However, none of the three patients with NPM1 mutation alone progressed to AML after 7–14 months follow-up, while the four subjects with concurrent FLT3 mutations invariably developed AML with a median interval of 12 months, with independent negative impact on progression-free survival (PFS) [62]. The gene discussed is FLT3; the disease is acute myeloid leukemia.